Market Cap 992.16M
Revenue (ttm) 32.33M
Net Income (ttm) -198.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -614.63%
Debt to Equity Ratio 0.00
Volume 10,306,600
Avg Vol 5,522,362
Day's Range N/A - N/A
Shares Out 89.14M
Stochastic %K 66%
Beta 2.23
Analysts Sell
Price Target $14.25

Company Profile

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 603 0070
Address:
201 Brookline Avenue, Suite 601, Boston, United States
NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:19 PM
$VERV Outstanding article that hits the mark on VERV's current state. So if you want to refresh your VERV insights or learn about VERV from scratch, this is a must read. https://beyondspx.com/article/verve-therapeutics-a-single-course-vision-for-cardiovascular-disease-backed-by-lilly-s-bet-verv
0 · Reply
biotech
biotech Jul. 28 at 6:03 PM
$SGMO ASGCT Nov. 20-21, 2025 delve into the latest advancements in targeted gene editing delivery strategies in vivo Invited Speaker: $SGMO Sonia Vallabh, PhD (Broad Institute) Talk Topic: AAV-mediated #epigenetic #editing for #prion disease also $VERV and $BEAM attending https://www.asgct.org/events/breakthroughs/program
1 · Reply
NwordFslur
NwordFslur Jul. 28 at 2:09 PM
$VERV what can I do with my options? Robinhood doesn't let me trade them. $5 strike
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 26 at 7:41 AM
$VERV this was fun. I expected the management to wait for the data then we would make much more than the 90% permium. But I will take the W and watch Lilly reap the spoils. For the record, ai think this drug will be worth 10b annual sales.
0 · Reply
WM_trader
WM_trader Jul. 25 at 3:59 PM
$VERV What are the expectations here with the news?
0 · Reply
Okadarlan
Okadarlan Jul. 25 at 3:49 PM
$VERV big crash immenent.
1 · Reply
masonat
masonat Jul. 25 at 1:34 PM
$VERV have been keeping up with the company and posting my thoughts here for a few years now. Was fun while it lasted! ✌🏼
0 · Reply
I_killed_the_kraken
I_killed_the_kraken Jul. 25 at 1:01 PM
$VERV watching today, huge news, currently halted
0 · Reply
AlertsAndNews
AlertsAndNews Jul. 25 at 12:55 PM
$VERV $LLY Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk VERV is t-12 halted still.
0 · Reply
MKRReformed
MKRReformed Jul. 25 at 12:50 PM
$VERV officially completed via $LLY Grats to all bulls
0 · Reply
Latest News on VERV
Lilly and Verve announce expiration of Verve tender offer

Jul 24, 2025, 8:00 AM EDT - 12 days ago

Lilly and Verve announce expiration of Verve tender offer

LLY


Lilly to buy gene-editing partner Verve for $1.3 billion

Jun 17, 2025, 12:57 PM EDT - 7 weeks ago

Lilly to buy gene-editing partner Verve for $1.3 billion

LLY


Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Jun 17, 2025, 8:31 AM EDT - 7 weeks ago

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

RGC SAGE


NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:19 PM
$VERV Outstanding article that hits the mark on VERV's current state. So if you want to refresh your VERV insights or learn about VERV from scratch, this is a must read. https://beyondspx.com/article/verve-therapeutics-a-single-course-vision-for-cardiovascular-disease-backed-by-lilly-s-bet-verv
0 · Reply
biotech
biotech Jul. 28 at 6:03 PM
$SGMO ASGCT Nov. 20-21, 2025 delve into the latest advancements in targeted gene editing delivery strategies in vivo Invited Speaker: $SGMO Sonia Vallabh, PhD (Broad Institute) Talk Topic: AAV-mediated #epigenetic #editing for #prion disease also $VERV and $BEAM attending https://www.asgct.org/events/breakthroughs/program
1 · Reply
NwordFslur
NwordFslur Jul. 28 at 2:09 PM
$VERV what can I do with my options? Robinhood doesn't let me trade them. $5 strike
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 26 at 7:41 AM
$VERV this was fun. I expected the management to wait for the data then we would make much more than the 90% permium. But I will take the W and watch Lilly reap the spoils. For the record, ai think this drug will be worth 10b annual sales.
0 · Reply
WM_trader
WM_trader Jul. 25 at 3:59 PM
$VERV What are the expectations here with the news?
0 · Reply
Okadarlan
Okadarlan Jul. 25 at 3:49 PM
$VERV big crash immenent.
1 · Reply
masonat
masonat Jul. 25 at 1:34 PM
$VERV have been keeping up with the company and posting my thoughts here for a few years now. Was fun while it lasted! ✌🏼
0 · Reply
I_killed_the_kraken
I_killed_the_kraken Jul. 25 at 1:01 PM
$VERV watching today, huge news, currently halted
0 · Reply
AlertsAndNews
AlertsAndNews Jul. 25 at 12:55 PM
$VERV $LLY Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk VERV is t-12 halted still.
0 · Reply
MKRReformed
MKRReformed Jul. 25 at 12:50 PM
$VERV officially completed via $LLY Grats to all bulls
0 · Reply
michipetruzale
michipetruzale Jul. 25 at 8:03 AM
$VERV whats happening with my shares?
1 · Reply
TwongStocks
TwongStocks Jul. 24 at 7:10 PM
$VERV NASDAQ Equity Corporate Actions Alert #2025 - 391 (UPDATED) Information Regarding the Tender Offer of Verve Therapeutics, Inc. (VERV) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-391 The tender offer by Eli Lilly & Co $LLY to acquire all of the outstanding common stock of Verve Therapeutics, Inc. $VERV expired one minute after 11:59 p.m. ET, on July 23, 2025. The subsequent merger is tentatively scheduled to close prior to the market open on July 25, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on July 24, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (July 25th) and will be suspended July 28, 2025. Tender offer is $10.50 & 1 Contingent Value Right (CVR) for each share of VERV held
0 · Reply
Mergerbrief
Mergerbrief Jul. 23 at 12:10 PM
$VERV / $LLY - Tender Offer Expires MergerBrief.com
0 · Reply
OMillionaires
OMillionaires Jul. 21 at 2:39 PM
$EDIT $260 mil market cap with $221 mil cash 10.5% short interest $LLY 's $VERV buyout seems to have been a floor and spark in the gene editing space... Blue skies over that $3.30 handle from Feb
1 · Reply
GeneInvestingTwitter
GeneInvestingTwitter Jul. 21 at 2:30 PM
$NTLA yes tons! $VERV buyout by Lily. Liu buying many times $PRME 51 million insider $CRSP buy last week
2 · Reply
jattboy
jattboy Jul. 12 at 12:49 AM
$VERV this stock is done now...spon it epnt even be on the market anymore...there is no upside to this stoxk anymore ...just liquidate ane move on people
0 · Reply
Esau815
Esau815 Jul. 10 at 3:34 AM
$VERV The only question regarding VERV is whether the CVR is worth 62 cents above deal price. Sek has 2.8MM shares so for him this is a $10MM CVR. Trial has to be initiated--not necessarily succeed--to clear the bar.
0 · Reply
sogenerous
sogenerous Jul. 7 at 5:12 PM
$PRME still around 1/3 of $VERV acq price despite being a platform company with superior assets, technology and commercialization prospects in rare disease with no competitors or treatments. VERV was essentially a single asset company targeting saturated heavily competitive and saturated PCSK9 market and there will be huge barrier to getting physicians and doctors to get on board. Key to understand imo verve acq price is the floor not the ceiling on any acq but preferred route is BD which is what I think will happen
1 · Reply
Albertowest
Albertowest Jul. 3 at 12:34 PM
$ESPR Sheldon is staying, he is part of the scheme for a BP to steal the company, I did some research after hearing all these delusional and conspiratorial theories and I must say they make sense. Look at this last acquisition by $LLY of $VERV at almost half of the IPO price. I’m pretty sure that what they are developing now they were developing it a long time ago.
1 · Reply
DrSilbergleit
DrSilbergleit Jul. 1 at 6:34 AM
YTD performance of genomics stocks: $VERV: +87% $EDIT: +68% $CRSP: +17% $DNA: +10%
0 · Reply
TargetsofInterest
TargetsofInterest Jun. 30 at 4:19 PM
1 · Reply
nycpupster
nycpupster Jun. 30 at 4:10 PM
$CRSP $VERV $PRME gene editing has big pump energy
0 · Reply